News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis

Posted on

Santalis Pharmaceuticals today announced it has enrolled its first patient into a single-center, open label, efficacy and tolerability proof of concept study using a unique 10% East Indian Sandalwood Oil (EISO) serum formulation for the treatment of mild to moderate plaque psoriasis. Patients will be at least 18 years of age with a maximum of 10% treatable body surface area […]Read More Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis